Search research articles
Contact Us
Filters
Showing results (31-40 of 42) with videos related to
Page
of 5
Sort By:
Therapeutic Advances in Medical Oncology
|
September 18, 2023
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Robert B Cameron, Jacobi B Hines, Valter Torri, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
February 5, 2022
Fluoxetine ameliorates mucopolysaccharidosis type IIIA
Antonella Capuozzo, Sandro Montefusco, Vincenzo Cacace, et al.
The EMBO Journal
|
September 15, 2023
TFEB and TFE3 control glucose homeostasis by regulating insulin gene expression
Adrien Pasquier, Nunzia Pastore, Luca D'Orsi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2025
Deep Learning Discriminates Thymic Epithelial Tumors Histological Subtypes Using Digital Pathology
Matteo Sacco, Erica Pietroluongo, Anna Di Lello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 10, 2024
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Jacobi B Hines, Robert B Cameron, Alessandra Esposito, et al.
Nature
|
July 3, 2020
A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome
Gennaro Napolitano, Chiara Di Malta, Alessandra Esposito, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 10, 2023
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
Antonio Nuccio, Giuseppe Viscardi, Fabio Salomone, et al.
Nature Communications
|
July 3, 2023
Loss of the batten disease protein CLN3 leads to mis-trafficking of M6PR and defective autophagic-lysosomal reformation
Alessia Calcagni', Leopoldo Staiano, Nicolina Zampelli, et al.
Nature Cell Biology
|
September 29, 2020
LC3 lipidation is essential for TFEB activation during the lysosomal damage response to kidney injury
Shuhei Nakamura, Saki Shigeyama, Satoshi Minami, et al.
EMBO Molecular Medicine
|
August 19, 2021
Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
Chiara Soldati, Irene Lopez-Fabuel, Luca G Wanderlingh, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 42) with videos related to
Sort By:
Page
of 5
Therapeutic Advances in Medical Oncology
|
September 18, 2023
What is the ideal endpoint in early-stage immunotherapy neoadjuvant trials in lung cancer?
Robert B Cameron, Jacobi B Hines, Valter Torri, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
February 5, 2022
Fluoxetine ameliorates mucopolysaccharidosis type IIIA
Antonella Capuozzo, Sandro Montefusco, Vincenzo Cacace, et al.
The EMBO Journal
|
September 15, 2023
TFEB and TFE3 control glucose homeostasis by regulating insulin gene expression
Adrien Pasquier, Nunzia Pastore, Luca D'Orsi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 13, 2025
Deep Learning Discriminates Thymic Epithelial Tumors Histological Subtypes Using Digital Pathology
Matteo Sacco, Erica Pietroluongo, Anna Di Lello, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 10, 2024
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Jacobi B Hines, Robert B Cameron, Alessandra Esposito, et al.
Nature
|
July 3, 2020
A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome
Gennaro Napolitano, Chiara Di Malta, Alessandra Esposito, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 10, 2023
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies
Antonio Nuccio, Giuseppe Viscardi, Fabio Salomone, et al.
Nature Communications
|
July 3, 2023
Loss of the batten disease protein CLN3 leads to mis-trafficking of M6PR and defective autophagic-lysosomal reformation
Alessia Calcagni', Leopoldo Staiano, Nicolina Zampelli, et al.
Nature Cell Biology
|
September 29, 2020
LC3 lipidation is essential for TFEB activation during the lysosomal damage response to kidney injury
Shuhei Nakamura, Saki Shigeyama, Satoshi Minami, et al.
EMBO Molecular Medicine
|
August 19, 2021
Repurposing of tamoxifen ameliorates CLN3 and CLN7 disease phenotype
Chiara Soldati, Irene Lopez-Fabuel, Luca G Wanderlingh, et al.
Page
of 5